TABLE 3.
Summary of adverse events. Values are expressed as frequencies [n (%)].
| Adverse event | Osi + bev (n = 38) | Che + bev (n = 58) | ||
|---|---|---|---|---|
| All grades | Grade ≥ 3 | All grades | Grade ≥ 3 | |
| Proteinuria | 13 (34.2) | 3 (7.9) | 17 (29.3) | 5 (8.6) |
| Thrombocytopenia | 12 (31.6) | 3 (7.9) | 15 (25.9) | 11 (19) |
| Neutropenia | 9 (23.7) | 2 (5.3) | 29 (50.0) | 14 (24.1) |
| AST/ALT elevation | 8 (21.1) | 2 (5.3) | 14 (24.1) | 6 (10.3) |
| Hypoproteinemia | 10 (26.3) | 1 (2.6) | 16 (27.6) | 5 (8.6) |
| Anemia | 7 (18.4) | 3 (7.9) | 13 (22.4) | 7 (12.1) |
| Fatigue | 8 (21.1) | 0 | 19 (32.8) | 10 (17.2) |
| Rash | 7 (18.4) | 0 | 2 (3.4) | 0 |
| Anorexia | 8 (21.1) | 2 (5.3) | 15 (25.9) | 6 (10.3) |
| Nausea | 7 (18.4) | 0 | 16 (27.6) | 4 (6.9) |
| Vomiting | 3 (7.9) | 0 | 10 (17.2) | 2 (3.4) |
| Headache | 4 (10.5) | 0 | 5 (8.6) | 0 |
| Oral mucositis | 5 (13.2) | 0 | 7 (12.1) | 0 |
| Pharyngodynia | 3 (7.9) | 0 | 6 (10.3) | 0 |
| Hypertension | 11 (28.9) | 5 (13.2) | 18 (31) | 6 (10.3) |
| Diarrhea | 9 (23.7) | 4 (10.5) | 14 (24.1) | 2 (3.4) |
| Bleeding | 8 (21.1) | 2 (5.3) | 12 (20.7) | 1 (1.7) |
WBC, white blood cell; ALT, alanine aminotransferase; AST, aspartate aminotransferase; osi + bev, osimertinib plus bevacizumab; che + bev, chemotherapy plus bevacizumab.